Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Other Non-Current Liabilities (2016 - 2020)

Historic Other Non-Current Liabilities for Niagen Bioscience (NAGE) over the last 10 years, with Q2 2020 value amounting to $250000.0.

  • Niagen Bioscience's Other Non-Current Liabilities fell 1467.58% to $250000.0 in Q2 2020 from the same period last year, while for Jun 2020 it was $250000.0, marking a year-over-year decrease of 1467.58%. This contributed to the annual value of $169000.0 for FY2019, which is 3854.55% down from last year.
  • According to the latest figures from Q2 2020, Niagen Bioscience's Other Non-Current Liabilities is $250000.0, which was down 1467.58% from $238000.0 recorded in Q1 2020.
  • Over the past 5 years, Niagen Bioscience's Other Non-Current Liabilities peaked at $503850.0 during Q3 2017, and registered a low of $155000.0 during Q3 2018.
  • Moreover, its 5-year median value for Other Non-Current Liabilities was $275000.0 (2018), whereas its average is $286329.8.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first plummeted by 6328.27% in 2018, then soared by 7970.3% in 2019.
  • Over the past 5 years, Niagen Bioscience's Other Non-Current Liabilities (Quarter) stood at $389010.0 in 2016, then dropped by 19.28% to $314000.0 in 2017, then decreased by 12.42% to $275000.0 in 2018, then crashed by 38.55% to $169000.0 in 2019, then skyrocketed by 47.93% to $250000.0 in 2020.
  • Its Other Non-Current Liabilities stands at $250000.0 for Q2 2020, versus $238000.0 for Q1 2020 and $169000.0 for Q4 2019.